Dorsomorphin (Compound C): Dual AMPK and BMP Pathway Inhibitor in Translational Research

Principle and Setup: Unlocking Dual-Pathway Inhibition

Dorsomorphin, also known as Compound C, stands at the forefront of bench-to-bedside research as a selective, reversible, and potent ATP-competitive AMPK inhibitor (Ki = 109 nM). Its unique molecular profile allows it to precisely target the AMPK signaling pathway—a master regulator of energy metabolism and autophagy regulation—while simultaneously acting as a robust BMP signaling inhibitor by blocking Smad 1/5/8 phosphorylation. This dual-action mechanism supports translational breakthroughs in metabolic disease, muscle atrophy, neural differentiation, and cancer research.

Recent advances underscore the importance of dissecting both AMPK and BMP/Smad pathways for comprehensive disease modeling. For example, the reference study by Ren et al. (IJBM 2025) showed that disrupting AMPK activity with Dorsomorphin abrogated the protective effects of Lycium barbarum polysaccharide on skeletal muscle mitophagy and atrophy, highlighting the compound’s pivotal role in experimental validation.

Dorsomorphin (Compound C) is supplied as a solid, insoluble in water/ethanol but readily soluble in DMSO (≥8.49 mg/mL with gentle warming and sonication), and is stable at -20°C. Typical usage concentrations are 4–40 μM in cell culture and 10 mg/kg for in vivo models via intraperitoneal injection.

Step-by-Step Workflow: Protocol Enhancements for Reliable Results

1. Compound Preparation and Handling

• Stock Solution: Dissolve Dorsomorphin in DMSO to create a ≥10 mM stock. Use gentle warming (≤37°C) and ultrasonication for complete dissolution. Avoid water or ethanol, as Dorsomorphin is insoluble in these solvents.
• Aliquoting: Prepare single-use aliquots to minimize freeze-thaw cycles. Store at -20°C in tightly sealed vials under desiccation.
• Working Solution: Dilute the stock into pre-warmed cell culture medium to achieve final concentrations (4–40 μM) immediately before use. Limit DMSO concentration to ≤0.1% to avoid cytotoxicity.

2. Experimental Design: Targeting AMPK and BMP/Smad Pathways

• Cellular Assays:
  • For inhibition of AMPK activity in hepatocytes or HeLa cells, pre-treat cells with Dorsomorphin 30–60 min before pathway stimulation (e.g., AICAR, glucose deprivation).
  • Monitor ACC phosphorylation inhibition (Western blot for p-ACC) as a direct downstream readout, expecting up to 80% reduction at optimal dosing.
  • To assess BMP4-induced SMAD phosphorylation inhibition, add Dorsomorphin prior to BMP4 stimulation; measure p-Smad 1/5/8 by immunoblotting (IC₅₀ = 0.47 μM).
• Autophagy and Mitophagy Assays: Use Dorsomorphin to disrupt AMPK/PINK1/Parkin-mediated autophagy regulation. Evaluate LC3 II/I ratio (autophagic flux), mitochondrial membrane potential, and ATP levels (e.g., JC-1, ATP assays).
• In Vivo Models: For animal studies (e.g., iron metabolism modulation or muscle atrophy), inject Dorsomorphin intraperitoneally at 10 mg/kg. Collect tissues for mRNA, protein, and histological analysis within 24–48 hours post-treatment.

3. Controls and Validation

• Always include vehicle (DMSO-only) and positive controls (e.g., AICAR for AMPK activation).
• Validate pathway inhibition by direct measurement of downstream targets (p-ACC, p-Smad 1/5/8, LC3 II/I, hepcidin mRNA).

Advanced Applications and Comparative Advantages

1. Muscle Atrophy and Metabolic Syndrome Models

In the landmark study by Ren et al. (IJBM 2025), Dorsomorphin was essential for unraveling the role of AMPK in mitophagy and muscle preservation under high-fat diet conditions. Blocking AMPK with Dorsomorphin negated the beneficial effects of Lycium barbarum polysaccharide, confirming the necessity of AMPK/PINK1/Parkin signaling in muscle health. These data-driven insights spotlight Dorsomorphin as the gold standard for dissecting metabolic and autophagic mechanisms in muscle atrophy and sarcopenic obesity.

2. Neural Stem Cell Differentiation

Dorsomorphin’s ability to inhibit BMP/Smad signaling is leveraged to promote self-renewal and neural induction in human embryonic stem cells. By suppressing BMP pathways, Dorsomorphin facilitates neural lineage commitment, outperforming less selective BMP inhibitors in both potency and reproducibility.

3. Iron Metabolism and Hepcidin Regulation

As a BMP signaling inhibitor, Dorsomorphin reduces hepatic hepcidin gene transcription, thereby increasing serum iron levels. This feature makes it an invaluable tool for probing the interplay between BMP/Smad and systemic iron homeostasis, relevant to studies of anemia, hemochromatosis, and chronic inflammation.

4. Cancer Research and Autophagy Modulation

In cancer research, Dorsomorphin’s selective inhibition of the AMPK signaling pathway enables precise dissection of metabolic reprogramming and autophagy regulation in tumor models. Its high selectivity over kinases such as PKA, PKC, and JAK3 minimizes off-target effects, enabling clearer mechanistic insight.

5. Strategic Positioning: Interlinking the Knowledge Base

Multiple authoritative articles expand on Dorsomorphin’s advanced applications:

• Dorsomorphin (Compound C): Powerful AMPK Inhibitor for Me... complements this article by offering troubleshooting scenarios and optimizing protocols for metabolic and autophagic studies.
• Strategic Deployment of Dorsomorphin (Compound C): Unrave... extends the discussion by integrating mechanistic insight, translational strategy, and advanced disease model applications, particularly in muscle atrophy and stem cell engineering.
• Dorsomorphin (Compound C): Strategic Deployment of Dual-P... contrasts and contextualizes Dorsomorphin’s dual-pathway inhibition with other pharmacological tools, highlighting its role in driving breakthroughs in metabolic disease and neural regeneration.

Troubleshooting and Optimization Tips

1. Solubility and Handling

• Incomplete Dissolution: If Dorsomorphin fails to dissolve in DMSO, extend sonication up to 5–10 minutes and verify temperature (<37°C). Avoid prolonged heating to prevent degradation.
• Precipitation in Media: Add stock to pre-warmed media slowly while vortexing to prevent precipitation. Always filter sterilize through a 0.22 μm filter if turbidity remains.

2. Biological Activity and Off-Target Effects

• Loss of Activity: Use freshly prepared solutions; avoid repeated freeze-thaw cycles. Dorsomorphin is labile in solution and degrades over time, especially at room temperature.
• Off-Target Effects: Although highly selective, Dorsomorphin may modestly inhibit ALK2 (a BMP receptor) and related kinases at high concentrations. Titrate carefully and validate with orthogonal pathway readouts.

3. Experimental Design

• Cytotoxicity: Limit DMSO concentration and confirm cell viability (e.g., MTT, Trypan Blue) at each tested dose.
• Temporal Kinetics: For acute pathway inhibition (e.g., AMPK, SMAD), 30–60 min pre-treatment is optimal. For chronic studies (e.g., neural differentiation), refresh Dorsomorphin daily to maintain consistent inhibition.

Future Outlook: Expanding the Translational Frontier

The dual-pathway inhibition profile of Dorsomorphin (Compound C) positions it as a strategic tool for next-generation translational research. Ongoing innovation in disease modeling—spanning sarcopenic obesity, metabolic syndrome, cancer, and neural regeneration—will continue to leverage Dorsomorphin’s unique ability to dissect the crosstalk between metabolic and differentiation pathways.

Emerging trends include combinatorial use with genetic knockdown (siRNA/shRNA) for pathway validation, CRISPR-based lineage tracing, and high-content screening in stem cell platforms. The integration of Dorsomorphin with advanced omics technologies promises finer mechanistic resolution and accelerated therapeutic discovery.

As highlighted in recent thought-leadership articles (Strategic Dual-Pathway Inhibition: Redefining Translation... and Strategic Leveraging of Dual AMPK and BMP Inhibition), the continued evolution of Dorsomorphin-centric workflows will shape the translational landscape—empowering researchers to unravel complex disease mechanisms and drive the next wave of precision therapeutics.